These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10172130)

  • 1. Potential effect of tacrine on expenditures for Alzheimer's disease.
    Lubeck DP; Mazonson PD; Bowe T
    Med Interface; 1994 Oct; 7(10):130-8. PubMed ID: 10172130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Alzheimer disease with tacrine: a cost-analysis model.
    Wimo A; Karlsson G; Nordberg A; Winblad B
    Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):191-200. PubMed ID: 9437436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic impact of the tacrine in the treatment of Alzheimer's disease.
    Henke CJ; Burchmore MJ
    Clin Ther; 1997; 19(2):330-45. PubMed ID: 9152571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacoeconomics of Alzheimer's disease.
    Fillit HM
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1139-44; discussion S1145-8. PubMed ID: 11142178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic considerations in Alzheimer's disease.
    Meek PD; McKeithan K; Schumock GT
    Pharmacotherapy; 1998; 18(2 Pt 2):68-73; discussion 79-82. PubMed ID: 9543467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
    Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S
    Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.